Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Iovance Biotherapeutics (0JDK) Drug Pipeline

5 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Iov-5001Colorectal Cancer, Non-small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Advanced Solid Tumors, Metastatic Solid Tumors, Triple Negative Breast Cancer (Tnbc), Unresectable Solid Tumorphase1AndPhase2Not Yet RecruitingA Study of IOV-5001 in Adults With Advanced Solid TumorsJul 29, 2026
Lifileucel, Ln-145Sarcoma, Soft Tissue Sarcoma (Sts), Undifferentiated Pleomorphic Sarcoma (Ups), Advanced Soft Tissue Sarcoma, Dedifferentiated Liposarcoma (Ddlps)Phase IIRecruitingA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaJul 28, 2026―
LifileucelMetastatic Melanoma, Unresectable Melanoma, Melanoma (Skin Cancer)Phase IIActive Not RecruitingA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaDec 09, 2025
Iov-3001Metastatic Melanoma, Unresectable Melanoma, Ocular Melanomaphase1AndPhase2RecruitingA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelApr 08, 2025
Ln-145/Ln-144Melanoma, Ewing Sarcoma, Soft Tissue Sarcoma, Rhabdomyosarcoma, Primary Central Nervous System CarcinomaPhase IRecruitingStudy of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsJul 17, 2024
LifileucelEndometrial CancerPhase IIRecruitingA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.Jun 25, 2024
Lifileucel Plus Pembrolizumab, Pembrolizumab With Optional Crossover PeriodMelanoma, Metastatic Melanoma, Unresectable MelanomaPhase IIIRecruitingStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.Feb 06, 2023
Iov-4001Metastatic Melanoma, Stage Iv Non-Small Cell Lung Cancer, Stage Iii Non-Small Cell Lung Cancer, Unresectable Melanomaphase1AndPhase2RecruitingA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerApr 29, 2022
Ln-145Metastatic Non Small Cell Lung CancerPhase IIRecruitingAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerOct 21, 2020
Il-2, Iov-2001, Low Dose Il-2, High Dose Il-2Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphomaphase1AndPhase2CompletedStudy of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLNov 04, 2019―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Iovance Biotherapeutics (GB:0JDK) have in its pipeline
Iovance Biotherapeutics GB:0JDK is currently developing the following drugs: Iov-5001, Lifileucel, Ln-145, Lifileucel, Iov-3001, Ln-145/Ln-144, Lifileucel Plus Pembrolizumab, Pembrolizumab With Optional Crossover Period, Iov-4001, Ln-145, Il-2, Iov-2001, Low Dose Il-2, High Dose Il-2, Pembrolizumab, Nab-Paclitaxel, Nivolumab, Ipilimumab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Lifileucel, Ln-145, Ln-145-S1, Nivolumab-Relatlimab, Ln-145, Ln-145 + Pembrolizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.